英文医学论文的撰写和投稿注意事项.pptVIP

 英文医学论文的撰写和投稿注意事项 中华医学杂志英文版 汪谋岳 论文的文题 作用 反映论文的主题或主要信息 吸引读者 论文的文题 要求 一般不超过100个字母 排版后不超过2行 可以不是完整的句子 最好反映文章的特色，如：若是随机对照试验，文题需要体现 最好反映研究对象，如动物种类等 论文的文题 论文的文题 论文的文题 关键词 一般列出3~10个,应尽量按照美国国立医学图书馆编纂的《Index Medicus》中的MeSH表选词。 如果MeSH表中找不到，可以用新词或相近的词 论文的摘要 200-300字 一般为四要素结构式，包括Objective (Background), Methods, Results, Conclusion JAMA分Context, Objective, Design and setting, Patients, Interventions， Main outcome measures, Results, Conclusions 论文的摘要 目的（背景） Background Eltrombopag is a new, orally active thrombopoietin-receptor agonist that stimulates thrombopoiesis. We evaluated its ability to increase platelet counts and facilitate treatment for hepatitis C virus (HCV) infection in patients with thrombocytopenia associated with HCV-related cirrhosis. 论文的摘要 方法 Methods Seventy-four patients with HCV-related cirrhosis and platelet counts of 20,000 to less than 70,000 per cubic millimeter were randomly assigned to receive eltrombopag (30, 50, or 75 mg daily) or placebo daily for 4 weeks. The primary end point was a platelet count of 100,000 per cubic millimeter or more at week 4. Peginterferon and ribavirin could then be initiated, with continuation of eltrombopag or placebo for 12 additional weeks. 论文的摘要 结果 Results At week 4, platelet counts were increased to 100,000 per cubic millimeter or more in a dose-dependent manner among patients for whom these data were available: in 0 of the 17 patients receiving placebo, in 9 of 12 (75%) receiving 30 mg of eltrombopag, in 15 of 19 (79%) receiving 50 mg of eltrombopag, and in 20 of 21 (95%) receiving 75 mg of eltrombopag (P0.001). Antiviral therapy was initiated in 49 patients (in 4 of 18 patients receiving placebo, 10 of 14 receiving 30 mg of eltrombopag, 14 of 19 receiving 50 mg of eltrombopag, and 21 of 23 receiving 75 mg of eltrombopag) whil